Last reviewed · How we verify
Albuterol/Salbutamol PRN
Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid relaxation and bronchodilation.
Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid relaxation and bronchodilation. Used for Acute bronchospasm relief in asthma, Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD), Exercise-induced bronchoconstriction prevention.
At a glance
| Generic name | Albuterol/Salbutamol PRN |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Beta-2 adrenergic agonist (short-acting) |
| Target | Beta-2 adrenergic receptor (ADRB2) |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Albuterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and airway dilation, providing rapid relief of bronchoconstriction. The PRN (as-needed) formulation is used for acute symptom relief in asthma and COPD.
Approved indications
- Acute bronchospasm relief in asthma
- Acute bronchospasm relief in chronic obstructive pulmonary disease (COPD)
- Exercise-induced bronchoconstriction prevention
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Tachycardia
- Muscle cramps
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (PHASE3)
- Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma (NA)
- Study to Investigate Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization With AIRSUPRA Compared to Albuterol as Needed in Adults With Mild Asthma (PHASE4)
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albuterol/Salbutamol PRN CI brief — competitive landscape report
- Albuterol/Salbutamol PRN updates RSS · CI watch RSS
- Organon and Co portfolio CI